{Reference Type}: Case Reports
{Title}: Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
{Author}: Rossi S;Costa R;di Federico A;Lo Bianco F;D'Angelo R;Asioli GM;De Giglio A;Sperandi F;Guarino M;Rinaldi R;Ardizzoni A;Cenacchi G;Gelsomino F;
{Journal}: J Thorac Oncol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 25
{Factor}: 20.121
{DOI}: 10.1016/j.jtho.2024.05.373
{Abstract}: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the standard of care for patients with advanced NSCLC and EGFR-sensitizing mutations. Both in osimertinib pivotal trials and in the post-marketing phase, asymptomatic creatinine phosphokinase elevation and clinically relevant muscle damage have been reported. However, the mechanisms underlying these conditions remain unclear. Herein, we report the first muscle biopsy description of osimertinib-induced myopathy and hypothesize that the mechanisms underpinning muscle toxicity could be driven by hyporegenerative mechanisms and mitochondrial dysfunction with subsequent reduced metabolic endurance, both directly linked to the inhibition of downstream molecular pathways mediated by EGFR in muscle cells.